Molecular allergens drive risk stratification and immunotherapy in Hymenoptera venom allergy.

ABSTRACT:

Background

Hymenoptera venom allergy is a major cause of life-threatening anaphylaxis. Molecular diagnostics have improved the characterisation of sensitisation patterns, although the clinical role of cross-reactive allergens such as DPPIV and hyaluronidases remains unclear.

Objective

To define IgE sensitisation to venom components, examine associations with clinical phenotypes, and assess the immunological impact of venom immunotherapy (VIT) in an Italian cohort.

Methods

In this monocentric study, 378 patients with documented Hymenoptera adverse reactions underwent extract-based and component-resolved diagnostics. A prospective subset (n = 113) was followed during VIT. Commercial venom extracts were characterised by inhibition assays.

Results

Systemic reaction

SUBMITTER: Scala E 

PROVIDER: S-EPMC12546951 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature